Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LpDessai: Combination Chemotherapy for Newly Diagnosed BPDCN
NCT03599960Phase 2Active, not recruiting
- Sponsor
- CHU de Besançon
- Start
- May 2019
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate, asparaginase escherichia coli, idarubicin and dexamethasone in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by CHU de Besançon. Started May 2019; status: active, not recruiting.
02
Drugs
methotrexateasparaginase escherichia coliidarubicindexamethasone
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT03599960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599960.